Drug intelligence / Profile preview

xiangfu yixue oral liquid

Development stage: Unknown
Lead developer: Beijing Asia-East Bio-Pharmaceutical
Administration: Oral

Overview

Xiangfu Yixue Oral Liquid is a Traditional Chinese Medicine (TCM) developed and manufactured by Beijing ASIA-EAST Biopharmaceutical (also known as Beijing Yadong Biopharmaceutical). It is primarily indicated for the treatment of Qi and Blood deficiency, particularly in oncology patients experiencing leukopenia (low white blood cell count) as a side effect of radiotherapy or chemotherapy. The formulation is designed to tonify the spleen, benefit the kidneys, and nourish the blood, thereby supporting hematopoietic recovery and improving immune function. It is an NMPA-approved pharmaceutical product in China, commonly used as supportive care to alleviate symptoms such as fatigue, dizziness, and palpitations in cancer patients.

Brand names: 香茯益血口服液
Other names: Xiangfu Yixue Koufuye

Beyond the preview

Go deeper on xiangfu yixue oral liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xiangfu yixue oral liquid.

Explore the full profile